Mathai Mammen

Mathai Mammen was the founder of Innoviva, Inc., founded in 1996, where the title held was Senior VP-Research & Early Clinical Development from 2011 to 2014.
Dr. Mammen was the founder of Theravance Biopharma, Inc., founded in 1997, where the title held was Senior Vice President-Research & Development from 2014 to 2016.
Current jobs include Chairman, President & Chief Executive Officer at Parabilis Medicines, Inc. since 2023; Director at Kelonia Therapeutics, Inc.; Director at MIT Jameel Clinic; Independent Director at Sandoz Group AG since 2024; Advisor at Foresite Capital Management LLC since 2019; and Senior Advisor at General Atlantic LP.
Former jobs include Independent Director at 10X Genomics, Inc. from 2017 to 2024; Senior Vice President at Merck Research Laboratories Massachusetts LLC from 2016 to 2017; Global Head-Research & Development at Janssen Research & Development LLC from 2017 to 2022; EVP-Pharmaceuticals, Research & Development at Johnson & Johnson in 2022; Vice President at American Society for Microbiology; and Senior Vice President at Merck & Co., Inc. from 2016 to 2017.
Education includes doctorate degrees from Harvard Medical School, Massachusetts Institute of Technology, and Harvard University, and an undergraduate degree from Dalhousie University.